Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

News

Sickle cell disease treatment has roots in lab of OMRF’s Dr. Rodger McEver

By sarah | News | 0 comment | 23 December, 2019 | 0

By Scott Meacham There is very big news this month for individuals and families affected by sickle cell disease (SCD). The U.S. Food and Drug Administration (FDA) has approved the first targeted treatment to reduce the frequency of pain crises in individuals living with SCD. This new drug — Adakveo® from Novartis — decreases theRead more

Life science investment boosts Oklahoma

By sarah | News | 0 comment | 30 April, 2019 | 0

By Scott Meacham Copyright © 2019, The Oklahoman At i2E, we like to invest in life sciences companies. About 40 percent of our portfolio is in therapeutics, diagnostics and medical devices. We recognize the abundant opportunity for these types of startups in Oklahoma, and we have developed the staff, expertise and partnerships to commercialize technologiesRead more

Oklahoma is getting the hang of the startup economy

By sarah | News | 0 comment | 15 May, 2018 | 0

By Scott Meacham Copyright © 2018, The Oklahoma Publishing Co. Anybody who’s ever heard me talk about building out Oklahoma’s innovation economy has heard me say that capital begets capital and deal flow begets deal flow. The challenge is that it takes a predictable continuum of investment capital to build a robust pipeline of startups,Read more

Oklahoma’s state-sponsored venture capital funds key to developing local firms

By sarah | Featured, News | 0 comment | 28 March, 2017 | 0

Scott Meacham Copyright © 2017, The Oklahoma Publishing Company There’s always a lot of discussion around pros and cons of state-sponsored venture capital funds. A recent Kauffman Foundation white paper even postulates that states should avoid state VC funds. The suggestion is that state-sponsored funds don’t match private VC funds when it comes to returnRead more

OKC pharma firm acquired in deal valued up to $665 million

By admin | News | 0 comment | 22 November, 2016 | 0

A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.

i2E portfolio company announces exit

By admin | News | 0 comment | 21 November, 2016 | 0

A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.

Biotech event on clinical trials coming to Oklahoma City on March 24

By admin | News | 0 comment | 8 March, 2016 | 0

On March 24, OKBIO, the Greater OKC Chamber and PhRMA (representing the country’s leading biopharmaceutical research and discovery companies) are hosting a unique opportunity for Oklahomans, from doctors to patients, to learn more about the power and the working parts of clinical trials.

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

618 E. Third Street, Suite 1
Tulsa, OK 74120
PHONE 918/582-5592
Click HERE for printable map with directions.
Copyright 2021 i2E, Inc. | All Rights Reserved
  • About i2E
  • Services
  • Investments
  • Development
    • Love’s Cup
      • Forms
      • High Growth
      • Small Business
      • Timeline
  • Portfolio 3
  • Contact
i2E